{
    "nct_id": "NCT03781362",
    "official_title": "A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "* Have a histologically or cytologically confirmed diagnosis of advanced solid tumor\n* Have advanced or metastatic disease refractory to standard curative or palliative therapy or contraindication to standard therapy\n* Be reasonably recovered from preceding major surgery or no major surgery within 4 weeks prior to the start of Day 1 treatment\n* Have a negative pregnancy test for females with child bearing age at screening and should not be breast feeding\n* Be willing to abstain from sexual activity or practice physical barrier contraception from study entry to 6 months after the last day of treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have peripheral neuropathy of Grade 3 or Grade 4 at screening\n* Have peripheral sensory neuropathy of Grade 2 or greater at screening\n* Have an interval from previous neurotoxic drugs less than 3 months unless reasonably recovered from all grades of neurotoxicity to grade 1 or lower as judged by the investigator\n* Have known hypersensitivity to chemotherapeutic agents\n* Have a history of thrombocytopenia with complications including hemorrhage or bleeding > Grade 2 that required medical intervention or any hemolytic condition or coagulation disorders that would make participation unsafe\n* Have unresolved toxicity from previous treatment or previous investigational agents; excluding alopecia\n* Is pregnant or breast-feeding",
    "miscellaneous_criteria": ""
}